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A calcimimetic agent acutely suppresses parathyroid hormone levels in
patients with chronic renal failure. The control of hyperparathyroidism in
patients with chronic renal failure continues to be a problem, particularly
when parathyroid hormone (PTH) suppression becomes refractory to
calcitriol activation of parathyroid cell 1,25-dihydroxyvitamin D receptors.
To evaluate whether parathyroid cell calcium receptor activation may be
useful in suppressing PTH levels, we tested the safety and effectiveness of
a novel calcimimetic agent in dialysis patients with hyperparathyroidism.
In a prospective, dose finding study, the calcimimetic agent, NPS R-568,
was administered orally to seven patients at the start of a hemodialysis
session and again 24 hours later. Plasma PTH, calcitonin and ionized
calcium levels were measured over a 48 hour period and patients were
observed for adverse events. Plasma PTH levels fell abruptly in all patients
after a single dose of the compound, with the maximum suppression
occurring within one to two hours after its administration. Following the
administration of low doses (40 or 80 mg), the suppressed PTH levels rose
to baseline values over 48 hours, whereas in patients who received high
doses (120 or 200 mg) the mean PTH level remained 51% below baseline.
Plasma calcitonin increased after the administration of both low and high
doses (peak effect within 4 to 6 hr), with levels always returning to baseline
by 48 hours. There were no episodes of hypocalcemia and no adverse
effects were reported. We conclude that the activation of parathyroid cell
calcium receptors by a novel calcimimetic compound is safe and effective
in acutely suppressing PTH secretion in dialysis patients with hyperpara-
thyroidism. Whether concomitant stimulation of calcitonin secretion will
provide added beneficial effects on bone remodeling remains to be
determined in long-term studies.
Hyperparathyroidism and bone disease occur in most patients
with chronic renal failure and can be managed in many by
judicious control of hyperphosphatemia and hypocalcemia, begin-
ning during the early stages of chronic renal insufficiency [1].
Some patients later develop more resistant forms of hyperpara-
thyroidism necessitating the use of high-dose pulse calcitriol
therapy [2, 3] to directly suppress PTH mRNA production
through activation of 1,25-dihydroxyvitamin D receptors [4].
While patients often respond to this form of PTH suppression,
refractoriness to calcitriol therapy continues to be a problem
because of either hypercalcemia [5] or the development of
nodular parathyroid gland histology that results in the loss of
1,25-dihydroxyvitamin D receptors [6]. Thus, new treatments are
needed that more reliably control excess PTH secretion and high
bone turnover in patients with chronic renal failure.
Recently, a calcium receptor in parathyroid and parafollicular
thyroid cells (C-cells) was identified [7, 8] and a series of novel
calcium receptor activating compounds was developed. These
organic allosteric activators of the calcium receptor cause a rapid
increase in intracellular calcium and an acute decrease in PTH
secretion. In thyroid C-cells the activated calcium receptor stim-
ulates calcitonin secretion. While preliminary data in animals and
humans with primary hyperparathyroidism suggest the potential
usefulness of an agent that stimulates calcium receptors to acutely
lower PTH levels, its effect in patients with chronic renal failure
has not been evaluated.
The purpose of the present study was to determine the short-
term safety of an oral calcimimetic agent, NPS R-568, in dialysis
patients with hyperparathyroidism and to assess its efficacy in
acutely suppressing PTH secretion.
METHODS
Subjects
The study subjects consisted of 8 male patients who had been
receiving chronic hemodialysis for 0.2 to 9.5 years (mean, 3 6 2
years); their ages ranged from 39 to 73 years. All were taking
calcium-containing phosphate binders (mean daily dose, 4.5 g)
and calcitriol (mean daily dose, 0.5 mg orally or intravenously).
None of the patients were receiving aluminum-containing medi-
cations. All signed a consent form explaining the protocol that was
approved by the Institutional Review Board of the University of
Washington.
Protocol
The study was open-labeled and consisted of four stages. The
calcimimetic agent, (R)-N-(3-methoxy-a-phenylethyl)-3-(29-chlo-
rophenyl)-1-propylamine hydrochloride) or NPS R-568, was ad-
ministered in four ascending doses after each patient was assigned
to two stages: either stages 1 (40 mg) and 3 (120 mg) or stages 2
(80 mg) and 4 (200 mg). At each stage, the patients received the
assigned dose of the compound on two consecutive days: the first
day a single oral dose was given at the beginning of a four hours
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hemodialysis treatment (dialysate calcium, 2.5 mEq/liter) and a
second identical dose was given 24 hours after the first dose when
the patient was not receiving dialysis. After each patient com-
pleted their first stage of treatment they entered a three to seven
week “washout” period before beginning their second stage.
Blood samples and vital signs (including Trousseau’s and
Chvostek’s signs) were obtained at baseline and at 1, 2, 4, 6, 10
and 24 hours after each dose. All heparinized blood samples were
immediately placed on ice and centrifuged within 30 minutes. The
plasma samples were stored at 220°C until they were assayed.
Assays
Plasma intact PTH was quantitated by an immunoradiometric
assay kit (Nichols Institute, San Juan Capistrano, CA, USA) that
uses antiserum raised against the intact molecule (Phoenix Life
Sciences Int., Montreal, Canada). The normal range is 15 to 65
pg/ml. Plasma calcitonin was determined by an immunocolorimet-
ric assay using antiserum developed against intact calcitonin
(Nichols Institute). The normal range is 5 to 11 pg/ml. Whole
blood ionized calcium was determined within three minutes of
collection using an automated NOVA 8 analyzer (Nova Biomed-
ical, Waltham, MA, USA). The normal range is 1.1 to 1.4
mmol/liter.
Statistics
Data were analyzed using Student’s paired t-test for comparison




Four patients received 40 mg and then 120 mg and three
additional patients received 80 mg and then 200 mg of NPS R-568.
It was well tolerated at all doses and no adverse effects were
attributed to the drug. One patient was removed from the study
when ECG evidence of atrial fibrillation was noted five hours after
receiving a single 80 mg dose. This event was believed to be
unrelated to the medication after subsequent evaluation revealed
that the patient had recurring self-limited asymptomatic atrial
fibrillation. The data from this patient were not included in the
analysis.
Plasma parathyroid hormone
Plasma PTH decreased with all doses of the drug but because of
the small number of patients in each dosing stage, the results were
analyzed after combining the patients into low (40 and 80 mg) and
high (120 and 200 mg) dose treatment groups. As shown in Figure
1, the PTH level in the low dose group decreased from 186 6 48
to 117 6 30 pg/ml (P 5 0.090) within one hour after dosing and
then rose rapidly to the baseline level by four hours. A similar
acute decrease was seen after the second dose (146 6 39 to 70 6
18 pg/ml at 2 hr; P 5 0.015) with the 48 hour value of 148 6 51
pg/ml not being significantly different from baseline. The PTH
nadir after the first dose ranged from 10 to 76% with 5 of 7
patients having a 30% or more decrease in PTH. The nadir after
the second dose ranged from 29 to 92% with 6 of 7 patients having
more than a 60% decrease in PTH.
In the high dose group the extent and duration of PTH
suppression was greater: PTH decreased from 218 6 52 to 81 6
22 pg/ml at the two hour nadir (P 5 0.016) and was 119 6 34
pg/ml at 24 hours (P 5 0.023 vs. baseline). On the second day,
PTH decreased further to a low of 47 6 9 pg/ml at two hours after
dosing and remained suppressed to 106 6 40 pg/ml at 48 hours
(P 5 0.019). The PTH nadir after the first dose ranged from 28 to
87% with 6 of 7 patients having a 60% or more decline in PTH.
The nadir after the second dose ranged from 28 to 81% where 6
of 7 patients had at least a 50% decrease in PTH.
Fig. 1. Plasma parathyroid hormone (PTH)
levels in dialysis patients receiving NPS R-568.
Values are the mean 6 SE. Arrowheads
indicate the time of a single oral dose. Low (E,
N 5 7) and high (f, N 5 7) dose groups are
defined in the Results section. *P , 0.05 versus
the baseline value.
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Plasma calcitonin
Baseline calcitonin levels ranged from 5 to 46 pg/ml (mean,
24 6 6 pg/ml) and were elevated in 5 patients. In the low dose
group, plasma calcitonin increased from 24 6 6 to 30 6 7 pg/ml
(P 5 0.021) at two hours after the initial dose and decreased to
baseline levels by 24 hours. On the second day calcitonin in-
creased from 25 6 5 pg/ml to 32 6 8 pg/ml (P 5 0.015) at two
hours after dosing (Fig. 2) and returned to baseline levels at 48
hours (25 6 6 pg/ml). The peak stimulation after the first dose
ranged from 20 to 53% and after the second dose it ranged from
8 to 64%.
In the high dose group the increases in calcitonin levels were
more marked: the peak calcitonin level was 44 6 10 pg/ml at four
hours (P 5 0.011) after the initial dose and the response on day 2
showed a peak level of 38 6 8 pg/ml (P 5 0.010) occurring four
hours after the second dose. The peak stimulation after the first
Fig. 2. Plasma calcitonin levels in dialysis
patients receiving NPS R-568. Values are the
mean 6 SE. Arrowheads indicate the time of a
single oral dose. Low (E; N 5 7) and high (f;
N 5 7) dose groups are defined in the Results
section. *P , 0.05 versus the baseline value.
Fig. 3. Whole blood ionized calcium levels in
dialysis patients receiving NPS R-568. Values
are the mean 6 SE. Arrowheads indicate the
time of a single oral dose. Low (E) and high
(f) dose groups are defined in the Results
section. *P , 0.05 versus the baseline value.
Atonsen et al: Calcimimetic suppression of PTH 225
dose ranged from 17 to 247% and 5 of 7 patients had at least a
100% increase in calcitonin. After the second dose the peak
calcitonin stimulation ranged from 12 to 58%.
Whole blood ionized calcium
In the low dose group, the baseline ionized calcium level of
1.24 6 0.02 mmol/liter decreased to 1.21 6 0.02 mmol/liter at 24
hours and 1.21 6 0.04 mmol/liter at 48 hours (P 5 NS). In the
high dose group, the blood ionized calcium decreased from 1.30 6
0.02 mmol/liter at baseline to 1.22 6 0.03 mmol/liter at 24 hours
(P 5 0.002) and 1.14 6 0.03 mmol/liter at 48 hours (P 5 0.005).
While this represented a significant decrease during treatment,
these values remained above the lower normal limit of 1.1
mmol/liter. None of the patients developed symptoms or signs of
hypocalcemia.
DISCUSSION
We have shown that NPS R-568, one member of a new class of
calcimimetic compounds, is safe and effective in acutely suppress-
ing circulating PTH in dialysis patients with hyperparathyroidism.
Each patient demonstrated a decline in PTH levels irrespective of
the dose administered. The inhibitory effect, which was maximum
within one to two hours of drug ingestion, was observed whether
patients were receiving hemodialysis or not, suggesting that the
dialysis procedure itself does not interfere with drug absorption or
action. For example, the acute PTH decline in the high dose group
during dialysis was 63%, while on the off-dialysis day PTH levels
declined by 61%. This acute PTH response is consistent with the
compound’s in vitro effects in cultured parathyroid cells where
PTH secretion is inhibited within minutes of exposure to the drug
(unpublished observations). This time course is consistent with its
presumed effect to acutely increase intracellular concentrations of
calcium, inositol 1,4,5-trisphosphate and diacylglycerol, similar to
what has been described for calcium regulation of PTH secretion
[7, 8]. Because there is no evidence that calcium receptors become
down-regulated following activation, our data suggest that multi-
ple daily dosing should be possible since consecutive doses each
produced similar acute declines in PTH. Whether these responses
would continue beyond the time in this study requires further
testing.
In contrast to its inhibitory effect on PTH secretion, the
calcimimetic agent stimulated calcitonin secretion at all doses
tested. This effect, which mimics its in vitro action in cultured
thyroid C cells (unpublished observations), was acute though not
sustained over a 24-hour period. Even with consecutive dosing,
plasma calcitonin returned to baseline in all patients, unlike the
PTH levels which remained suppressed. This disparity in response
to calcium receptor activation may relate to tissue specific differ-
ences in secondary signaling. For example, calcium inhibition of
PTH secretion occurs, in part, by decreasing PTH mRNA pro-
duction while calcium activation of thyroid C-cells stimulates
calcitonin secretion without altering calcitonin mRNA synthesis
[9]. Interestingly, recent studies in uremic rats have found that
calcium regulates calcitonin secretion in a sigmoidal relationship
within the range of normal calcium levels [10]. Thus, even though
the calcium range for calcitonin regulation may not be as narrow
as the range for PTH regulation, the calcium receptor in both of
these cell types may have their responses to calcimimetic therapy
modified by the ambient calcium concentration.
Calcium receptor activation in uremic patients with hyperpara-
thyroidism is expected to decrease bone turnover. By lowering
PTH levels there will be a decrease in osteoblast and osteoclast
activity resulting in reduced bone turnover [1]. At the same time,
a raised calcitonin level may reduce bone resorption further since
calcitonin acts directly on osteoclasts to decrease their activity [12,
13]. This would be consistent with previous reports showing that
endogenous calcitonin levels in dialysis patients have a beneficial
role on bone remodeling [14, 15]. Whether calcium receptor
activation therapy has the potential to profoundly suppress bone
resorption long-term remains to be determined. It will also be
important to identify individuals with the appropriate PTH level
for which calcimimetic therapy will be the most useful. For
example, most of our dialysis patients in this study had only mild
hyperparathyroidism and generally would not be candidates for
further suppression of PTH with either calcitriol or a calcimimetic
[1].
Ionized calcium levels declined in some of the patients who
received the higher doses of the calcimimetic agent. This was
especially apparent on the second day after consecutive dosing
where a mean decrease of 12% from baseline was noted in the
high dose group at 48 hours. Despite these declines none of the
patients developed signs or symptoms of hypocalcemia. While the
mechanism for the decrease in calcium levels was not determined
from these studies, we speculate that reduced bone turnover
induced by the changes in PTH and calcitonin, decreased the
egress of calcium from this mineralized compartment. This would
be comparable to the calcium lowering effect of parathyroidec-
tomy, though in theory, calcimimetic therapy would be less likely
to cause severe hypocalcemia because its acute effects are revers-
ible and dose responsive.
This study was limited by design to a small sample size and a
short duration of treatment to establish acceptable doses that can
be used in subsequent long-term trials. Future studies must also
examine more severe forms of hyperparathyroidism and the bone
histologic response to chronic calcium receptor activation. The
issue of whether prolonged calcimimetic therapy will be effective
in those uremic patients who develop reduced parathyroid cell
calcium receptor expression [16] will also have to be resolved.
However, while it remains to be established whether this partic-
ular calcimimetic agent will have long-term effectiveness, the
results of this study suggest that compounds which enhance the
activation of the calcium receptor will likely have a role in the
chronic management of renal osteodystrophy.
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